Carfilzomib for Relapsed or Refractory Multiple Myeloma

The Lancet Oncology - United Kingdom
doi 10.1016/s1470-2045(17)30859-8
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Elsevier BV

Related search

Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Study

American Journal of Hematology
Hematology
2019English

Carfilzomib Monotherapy in Japanese Patients With Relapsed or Refractory Multiple Myeloma: A Phase 1/2 Study

Cancer Science
Cancer ResearchMedicineOncology
2019English

Bendamustine in Patients With Relapsed or Refractory Multiple Myeloma

European Journal of Medical Research
Medicine
2010English

Bendamustine, Pomalidomide, and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma

Blood Cancer Journal
OncologyHematology
2018English

Isatuximab Plus Carfilzomib/Dexamethasone Versus Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: IKEMA Phase III Study Design

Future Oncology
MedicineCancer ResearchOncology
2020English

Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma With Extramedullary Disease

Cancers
Cancer ResearchOncology
2020English

Emerging Role of Carfilzomib in Treatment of Relapsed and Refractory Lymphoid Neoplasms and Multiple Myeloma

Core Evidence
MedicineReviewsReferencesPharmacology
2011English

A Phase I/Ii Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

Clinical Cancer Research
Cancer ResearchOncology
2019English

Optimizing the Use of Lenalidomide in Relapsed or Refractory Multiple Myeloma: Consensus Statement

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy